Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OurofinoBSP:OFSA3 +2.25%75 Price-to-Tangible-Book is 1.89 as of Sep. 21, 2026. GuruFocus rates BSP:OFSA3 with a GF Score™ of 75/100 and a GF Value™ of R$27.13 (Fairly Valued). The stock has 2 warning signs investors should review. Among 839 Drug Manufacturers companies, Ourofino ranks better than 58.52% on this metric.
As of today (2026-09-21), Ourofino's share price is R$26.38. Ourofino's Tangible Book per Share of Jun. 2026 for the quarter that ended in Jun. 2026 was R$13.92. Hence, Ourofino's Price to Tangible Book Ratio of today is 1.89.
The historical rank and industry rank for Ourofino's Price-to-Tangible-Book or its related term are showing as below:
BSP:OFSA3'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.6 Med: 2.93 Max: 7.13
Current: 1.9
During the past 13 years, Ourofino's highest Price to Tangible Book Ratio was 7.13. The lowest was 1.60. And the median was 2.93.
BSP:OFSA3's Price-to-Tangible-Book is ranked better than 58.52% of 839
companies
in the Drug Manufacturers industry
Industry Median: 2.3
vs BSP:OFSA3: 1.90
A closely related ratio is called PB Ratio. As of today, Ourofino's share price is R$26.38. Ourofino's Book Value per Sharefor the quarter that ended in Jun. 2026 was R$15.38. Hence, Ourofino's P/B Ratio of today is 1.72.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Ourofino Price-to-Tangible-Book Related Terms
Ourofino Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Ourofino's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:OFSA3 vs ZTS, UTHR, VTRS: Price-to-Tangible-Book Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ourofino's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ourofino Price-to-Tangible-Book vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ourofino's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Ourofino's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Ourofino (BSP:OFSA3) has a Price-to-Tangible-Book of 1.89 as of Sep. 21, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Ourofino and its competitors. According to the industry distribution chart, Ourofino ranks #348 out of 839 companies in the Drug Manufacturers industry, placing it in the top 41.5%.
Is Ourofino's Price-to-Tangible-Book too high?
Ourofino's current Price-to-Tangible-Book is 1.89. The Drug Manufacturers industry median Price-to-Tangible-Book is 2.30. Ourofino's value of 1.89 is 17.8% below this industry median. Based on the distribution chart, Ourofino ranks #348 out of 839 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ourofino has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ourofino's Price-to-Tangible-Book compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ourofino ranks #348 out of 839 companies for Price-to-Tangible-Book. This puts Ourofino in the upper half of its industry. The industry median Price-to-Tangible-Book is 2.30. Ourofino's value of 1.89 is 17.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Drug Manufacturers company?
The median Price-to-Tangible-Book among Drug Manufacturers companies is 2.30, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ourofino's current Price-to-Tangible-Book of 1.89 is 17.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Ourofino and its competitors. For the Drug Manufacturers industry, the median Price-to-Tangible-Book is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ourofino's current Price-to-Tangible-Book is 1.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ourofino stock overvalued right now?
Based on GuruFocus' analysis, Ourofino (BSP:OFSA3) is currently considered Fairly Valued. The stock's GF Value™ is R$27.13, compared to a current price of R$26.38 — trading 2.8% below its estimated fair value. The current Price-to-Tangible-Book is 1.89 and 17.8% below the Drug Manufacturers industry median of 2.30. Ourofino's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Ourofino (BSP:OFSA3), the current Price-to-Tangible-Book is 1.89 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ourofino (BSP:OFSA3) Overvalued in 2026?
Based on GuruFocus' analysis, Ourofino stock appears to be undervalued.
The current stock price of R$26.38 is trading 2.8% below its estimated GF Value™ of R$27.13.
GuruFocus considers Ourofino to be Fairly Valued.
Key valuation signals for BSP:OFSA3:
Price-to-Tangible-Book: 1.89
GF Value™: R$27.13 vs. price of R$26.38 (2.8% below fair value)
Industry Position: 17.8% below the Drug Manufacturers median (#348 of 839)
No single metric tells the full story. See the BSP:OFSA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ourofino SA is engaged in research, development, production and sales of medicines, vaccines and other veterinary products. The company's reportable segments are Production animals, Companion animals, and International operations. It generates maximum revenue from the Production animals segment. The product portfolio includes Anticoccidials, Antimastitics, Biological, Ectoparasiticides, Endectocides, and others.
75GF Score
Get the complete analysis for BSP:OFSA3
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:OFSA3 has been successfully added to your 
